Krempa David sold $229K of ETON

Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO ® (miltefosine) Capsules ● Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States ● Eton has integrated full Eton Cares® patient support, including $0

Eton Pharmaceuticals (ETON) stock has surged from $30 to over $60, driven by record Q2 sales of $37.6M (up 99% YoY) and adjusted EPS of $0.43. Jim Cramer advised taking partial profits. Management raised 2026 revenue guidance to over $145M but faces risks like gross margin compression and insider selling.

Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% YoY, driven by HEMANGEOL relaunch and pediatric endocrinology growth. FY 2026 revenue guidance raised to over $145M. Adjusted EBITDA was $16.2M (43% margin). ASN-001 licensing and study costs total $7M. Non-GAAP net income was $14.3M ($0.43/diluted share).

Analysts upgraded Eton Pharmaceuticals' (ETON) 2026 revenue forecast to $150M (up 42% YoY) and EPS to $1.09 (up 145%). The price target increased 30% to $71.00. The stock gained 51% in the last 7 days. Analysts expect growth to accelerate, outpacing industry averages.

Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% year over year, driven by HEMANGEOL sales. Net income was $11.6M, or $0.35/share, versus a net loss in Q2 2025. The company raised 2026 revenue guidance to over $145M and expects adjusted EBITDA margin of at least 35%.

Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.59M versus $18.93M a year earlier, and net income of $11.58M versus a $2.59M loss. The company raised full-year 2026 revenue guidance to at least $145M. Eton also licensed ASN-001 and named Danka Radosavljevic COO.